FDA Grants RMAT Designation to Atsena Therapeutics’ Gene Therapy for X-linked Retinoschisis
The designation aims to expedite development of ATSN-201 for X-linked retinoschisis, a rare inherited retinal disease with no approved treatment.The…
Atsena Secures FDA Fast Track Designation for ATSN-201 to Treat X-Linked Retinoschisis
With no approved treatments for XLRS, another promising gene therapy enters the fray. Atsena Therapeutics (North Carolina, USA) announced that…
latest posts
